Reading, United Kingdom (4 December 2017)
Convatec Group Plc (“Convatec” or “the Group”) today announces changes to the organisational structure of the Group and membership of its Executive Committee.
From January 1st 2018 Convatec’s four franchises will be led by Franchise Presidents who will report directly to the Group Chief Executive Officer and who will be members of the Executive Committee.
The Franchise Presidents will be responsible for leading the development and delivery of their worldwide strategic plans across all Convatec’s markets, including the Marketing and R&D organisations within their Franchise and working closely with the key functional areas of Convatec such as Sales, Regional Marketing, Regulatory and Quality Assurance, Manufacturing and Supply Chain operations and Business Development, to ensure alignment and collaboration.
These changes to the organisational structure will drive an enhanced focus on performance across the Group’s businesses, leveraging the strong pipeline of new products and the Group’s leading market positions.
The roles of the Regional Presidents and all other members of the Executive Committee will remain unchanged. The changes will be effective 1 January 2018.
Appointments of Franchise Presidents
Advanced Wound Care will now be led by Peter Byloos, who is joining Convatec from the investment company Gimv, where he was the Partner for healthcare. Before Gimv Peter was CEO of Handicare, and President EMEA for CR Bard. Fiona Adam has decided to transition from her current role but has agreed to remain with ConvaTec in a consultative capacity.
Ostomy Care: Erik Zimmer will continue as VP & General Manager of the Ostomy Care Franchise and will join the Executive Committee, reporting to the Group Chief Executive. An announcement on the appointment of a President for the Ostomy Care Franchise will be made in due course.
Continence and Critical Care: Frank Gehres, who is currently the Interim President of EMEA, has been appointed as President of the Continence and Critical Care Franchise. Mads Haugaard will report to Frank as Vice President and General Manager.
Infusion Devices: John Lindskog will continue in his current role as President with responsibility for the Infusion Devices Franchise.
Following these changes, Symeria Hudson, previously President Global Franchises and Innovation, will be leaving the Company with effect from 31 December 2017.
Paul Moraviec, Chief Executive Officer of Convatec, said:
“These important changes to our organisation will drive a greater focus on the leadership of our Franchises and on their performance as business units of Convatec, as well as providing better leverage of our strong new product pipeline. I am confident that this new structure will enable us to drive increased value from our leading market positions across each of the businesses.
Peter brings strong leadership and experience to the Advanced Wound Care Franchise and I welcome him to Convatec. I would also like to thank Symeria for her contribution to the Group and wish her well in her future career.”
Further Senior Management Appointments
The Group is also very pleased to announce the appointment of Kjersti Grimsrud as President of the EMEA Region. Kjersti joins Convatec from Alere, Inc where from 2014 she was President Europe and the Middle East and President International. Kjersti was a member of the initial team at Axis-Shield, which in 2011 was acquired by Alere.
In addition, Convatec has appointed Sean McGrath as EVP Global Human Resources. Sean joins Convatec from the World Bank Group where he was VP Human Resources from 2012. Prior to his current role, in 2008 Sean was appointed as the inaugural HR Director for the Health Service Executive in Ireland where he led that organisations’ change programme.
Marc Reuss, previously EVP Global Human Resources will be leaving Convatec with effect from 31 December 2017.
Paul Moraviec, Chief Executive Officer of Convatec, said:
“I am delighted to welcome Kjersti and Sean to Convatec and I am certain that they will make a most valuable contribution to the future success of the Company. I would also like to thank Marc for his role in seeing Convatec through a critical phase in the development of the Company.”
Bobby Leach, VP Group Corporate Affairs, Convatec +44 (0)7770 842 226
Alastair Elwen, Finsbury +44 (0)207 251 3801
Analysts and Investors
John Crosse, VP Investor Relations, Convatec +44 (0)7500 141 435
Kirsty Law, Director Investor Relations, Convatec +44 (0)7470 909 582
Convatec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. Convatec’s products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about Convatec, please visit www.convatecgroup.com where a copy of this announcement can also be found.
# # #
Download PRESS RELEASEPDF
Organisation AppointmentsRead more
FY2017 guidance and third quarter updateRead more
Convatec Introduces GentleCath™ Glide and me+™ Continence Care Programme for Intermittent Catheter Users in EuropeRead more
Scrip DividendRead more
Appointment to Executive CommitteeRead more
Convatec appoints two Non-Executive DirectorsRead more
Convatec Launches Natura™ Convex Accordion Flange™, Designed to Make Ostomy Pouch Application Easier and More ComfortableRead more
Convatec Announces 2017 Interim resultsRead more
03 August 2017 - Board ChangesRead more
Convatec Announces Acquisition of Woodbury HoldingsRead more
Announcement on Board of DirectorsRead more